Navigation Links
Bioniche Pharma Launches Ibutilide Fumarate Injection
Date:1/12/2010

LAKE FOREST, Ill., Jan. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert® from Pfizer Inc.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma will supply Ibutilide Fumarate Injection in 0.1 mg/mL, 10mL vials.

This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please refer to the Bioniche Pharma website at www.bionichepharma.com for the complete prescribing information for this product, including the boxed warning.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in
'/>"/>

SOURCE Bioniche Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
2. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
3. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014 Imago ... today announced a $26.5 million Series A financing ... firm founded by a team of accomplished investment ... investors participating in the round include Frazier Healthcare, ... Representatives from Clarus Ventures and Frazier Healthcare will ...
(Date:10/31/2014)... ARBOR, Mich. , Oct. 31, 2014 /PRNewswire/ ... immune modulators to treat autoimmune disease and cancer, ... of novel synthetic RORgamma agonist product candidates will ... Society for Immunotherapy of Cancer (SITC) being held ... & Convention Center, National Harbor, MD.  The poster, ...
(Date:10/31/2014)... 31, 2014 Investor-Edge has initiated ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ... these five companies can be accessed at: http://investor-edge.com/register ... NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow ...
Breaking Medicine Technology:Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5
... HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 18, 2007 - ... a new 42 month follow-up study of ... evaluated symptomatic,progress of U.S. patients involved in ... 2003. Individuals in the study were assessed,for ...
... at American Association for Cancer Research ... /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, Inc. , a ... commercializing proprietary product,candidates for the treatment ... positive results from preclinical studies using ...
Cached Medicine Technology:Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207,for BPH 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 2Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 3Adventrx Announces Positive Data From Multidrug Therapy With,CoFactor 4
(Date:10/31/2014)... TheHardwareCity.com is the place to purchase home ... space heaters are available at the online store. Now, ... 1500w portable electric space heater. , The space heater ... an energy efficient way to heat a small space ... produce 1500 Watts, ensuring a quick warm up period. ...
(Date:10/31/2014)... (PRCHN) at Case Western Reserve University School of ... million in federal grants awarded to improve community ... Disease Control and Prevention (CDC) renewed the PRCHN,s ... funds will support the center,s ongoing efforts in ... interventions that prevent and reduce chronic disease in ...
(Date:10/31/2014)... CA (PRWEB) October 31, 2014 ... also has amazing health effects for practitioners. ... by a Doctor of Science and Movement specializing ... his dedication to pelvic floor reeducation that traditional ... urinary incontinence, Diastasis Recti, Prolepses, etc. , The ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... say that either they or a family member have ... latest issue of The Gerontological Society of America,s ... which goes on to show that Americans strongly support ... end-of-life health care wishes. , This PP&AR , ... features 12 articles that present new ways of understanding ...
Breaking Medicine News(10 mins):Health News:Big Heat 1500w Electric Space Heater Now Available at TheHardwareCity.com 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... disease are receiving implantable cardioverter-defibrillators (ICDs) to maintain proper ... the 1980s, but little is known about how well ... 1 percent of recipients. A report in the April ... the largest pediatric experience to date. It finds the ...
... In a major step toward a practical energy ... development of a new generation of sub-microscopic nanomotors that ... motors. Their study is scheduled for the May 27 ... the new study, Joseph Wang and colleagues point out ...
... Campaign Encourages Consumers to Get Active and Give Back By Logging Miles ... ... A healthy lifestyle is always,important and to encourage consumers to get active, ... Breast,Cancer Organization with a donation of up to $200,000. Running from May ...
... Management to Host Conference Call Today at 11:30 a.m. ET ... a provider of liquid nutritional, functional foods, beverages and,nutritional supplements, ... 2008., Financial and operational highlights for First Quarter ... year period to $1.6 million -- Gross profit was ...
... Fla., May 1 Blue Cross and ... David Pizzo has been appointed Market,President - ... http://www.newscom.com/cgi-bin/prnh/20080501/CLTH034 ), (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ... ), Pizzo has served in a ...
... Mich., May 1 Perrigo Company,(Nasdaq: PRGO ... Directors declared a,quarterly dividend of $0.05 per share, ... on May 25, 2008., Perrigo Company is ... distributes over-the-counter (OTC) and prescription,pharmaceuticals, nutritional products, active ...
Cached Medicine News:Health News:Largest study to date finds benefits of ICDs in children 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 2Health News:XELR8 Holdings Announces Record First Quarter Revenue 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 4Health News:XELR8 Holdings Announces Record First Quarter Revenue 5Health News:XELR8 Holdings Announces Record First Quarter Revenue 6Health News:XELR8 Holdings Announces Record First Quarter Revenue 7Health News:XELR8 Holdings Announces Record First Quarter Revenue 8Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2
Magniclear is the first presbyopic lens to combine the clear distance optics of a spherical lens, the intermediate visual performance of a multifocal and the predictably crisp, near power of a bifoca...
... is a simultaneous vision lens ... Through a series of front ... LifeStyle Gp delivers up to ... its multi-aspheric center-distance design works ...
Gendron ophthalmic eye surgery stretcher....
... surgical stretcher. M-701 Stretcher has a ... to 32 in., measured with a ... a high range, 28 in. to ... pad can be supplied optionally. Vinyl ...
Medicine Products: